ClinicalTrials.gg
CompletedNCT04795037Updated Jul 21, 2022

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

A Phase 1 interventional study of CU06-1004, Single dose and CU06-1004, Multiple doses in Diabetic Macular Edema, sponsored by Curacle Co., Ltd.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-21.

Sponsored by Curacle Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
95th of 244
81 · median 45
Started
2021
with 12 others
Phase 1
43 of 276
3 open now
Registered
219th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 95th largest by enrollment of the 244 interventional ones that give a count, is one of 13 that started in 2021, is one of 43 in phase 1, and was the 219th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
  • Endothelial dysfunction blocker
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, adult, male or female (of non- only), 19-55 years of age, inclusive, at screening.
  2. (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening.
  3. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on subject self-reporting.
  4. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.
  5. Female must be of non-childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing:

    • hysteroscopic sterilization;
    • bilateral tubal ligation or bilateral salpingectomy;
    • hysterectomy;
    • bilateral oophorectomy; or be with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.
  6. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing.

    (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomized less than 4 months prior to the first dosing must follow the same restrictions as a non-vasectomized male).

  7. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing.
  8. Able to swallow multiple capsules.
  9. Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.
  3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  4. History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
  5. History or presence of or idiosyncratic reaction to the study drug or related compounds.
  6. Female subjects of .
  7. Female subjects with a positive pregnancy test at screening or first check-in or who are lactating.
  8. Positive urine drug or alcohol results at screening or first check-in.
  9. Positive results at screening for (HIV), surface antigen (HBsAg) or virus (HCV).
  10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg, at screening.
  11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
  12. interval is >460 msec (males) or >470 msec (females) or has findings deemed abnormal with clinical significance by the PI or designee at screening.
  13. Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements (especially sulforaphane-containing supplement) beginning 14 days prior to the first dosing and throughout the study. After randomization, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee.
    • Food and beverages containing xanthines/caffeine for 24 hours prior to the first dosing (small amounts of caffeine derived from normal foodstuffs e.g.,250 mL/8 oz./1 cup decaffeinated coffee or other decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be considered a deviation to this restriction).
    • Food and beverages containing alcohol for 48 hours prior to the first dosing.
    • Food and beverages containing grapefruit/Seville orange for 14 days prior to the first dosing.
    • Food and beverages containing vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard) and charbroiled meats for 14 days prior to the first dosing.
  14. Has received COVID-19 vaccine within 30 days of first dosing and until the end of the study.
  15. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study.
  16. Is lactose intolerant (FE cohort only).
  17. Donation of blood or significant blood loss within 56 days prior to the first dosing.
  18. Plasma donation within 7 days prior to the first dosing.
  19. Participation in another clinical study within 30 days prior to the first dosing. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the first dose of study drug in the current study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    CU06-1004 for SAD

    * Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts * 6 of out 8 subjects per cohort will be randomized to receive CU06-1004

    Drug: CU06-1004, Single dose

  • Placebo comparator
    Placebo for SAD

    * Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts * 2 of out 8 subjects per cohort will be randomized to receive placebo

    Drug: Placebo

  • Experimental
    CU06-1004 for MAD

    * Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts * 6 of out 8 subjects per cohort will be randomized to receive CU06-1004

    Drug: CU06-1004, Multiple doses

  • Placebo comparator
    Placebo for MAD

    * Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts * 2 of out 8 subjects per cohort will be randomized to receive placebo

    Drug: Placebo

Interventions

  • Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)* *Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5

    Also known as: SAC-1004, CU06, CU06-RE

  • Multiple doses of CU06-1004, 7 days, 3 dose levels*, oral capsule *The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD

    Also known as: SAC-1004, CU06, CU06-RE

  • DrugPlacebo

    Placebo matched to CU06-1004, oral capsule

06

What researchers measure

Primary outcomes

  1. The number and severity of treatment emergent adverse events (TEAEs)

    To assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.

    Time frame: From the date of first dose through 7 days after the last dose

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    To assess Cmax of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

    Time frame: Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)

  2. Time to reach maximum plasma concentration (Tmax)

    To assess Tmax of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

    Time frame: Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)

  3. Area under the concentration-time curve (AUC)

    To assess AUC of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

    Time frame: Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)

  4. Terminal elimination rate constant (Kel)

    To assess Kel of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

    Time frame: Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)

  5. Terminal elimination half-life (t½)

    To assess t½ of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

    Time frame: Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)

  6. Maximum plasma concentration (Cmax) under fed conditions

    To assess Cmax of single oral dose under fed conditions

    Time frame: Day 1 through Day 4 (SAD)

  7. Area under the concentration-time curve (AUC) under fed conditions

    To assess AUC of single oral dose under fed conditions

    Time frame: Day 1 through Day 4 (SAD)

  8. Amount of unchanged drug excreted in the urine collection (Ae)

    To assess Ae of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

    Time frame: Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)

  9. Renal Clearance (CLR)

    To assess CLR of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

    Time frame: Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)

  10. Fraction of drug excreted unchanged in urine (Fe)

    To assess Fe of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

    Time frame: Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)

07

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
08

References and documents

Publications

  • Maganti L, Panebianco DL, Maes AL. Evaluation of methods for estimating time to steady state with examples from phase 1 studies. AAPS J. 2008;10(1):141-7. doi: 10.1208/s12248-008-9014-y. Epub 2008 Feb 28. PubMed 18446514 ↗
  • Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419. PubMed 3450848 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Mar 2022, 7 months.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 12, 2021
StartActual
Jul 15, 2021
Primary completionActual
Mar 2, 2022
CompletionActual
Jun 25, 2022
Last update
Jul 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04795037
Lead sponsor
Curacle Co., Ltd.
Collaborators
KCRN Research, LLC
Responsible party
Sponsor
First posted
Mar 12, 2021
Start date
Jul 15, 2021
Primary completion
Mar 2, 2022
Completion
Jun 25, 2022
Last update
Jul 21, 2022

Study contacts

Ji-Hye Kang, Ph.D
study director · Curacle Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CU06-1004

Start the discussion